Reckitt Benckiser 'disappointed' as FDA approves production of generic drug

The Food and Drug Administration (FDA) has given the green light for two drug manufacturers to produce a generic version of Reckitt Benckiser's SUBOXONE tablets in the US, dealing a big blow to the consumer products giant.

The Food and Drug Administration (FDA) has given the green light for two drug manufacturers to produce a generic version of Reckitt Benckiser's SUBOXONE tablets in the US, dealing a big blow to the consumer products giant.

Reckitt announced on Monday morning that two unnamed manufacturers had received approval to make the drug, which is used in the treatment for the chronic diseases of addiction.

The new comes after RB Pharmaceuticals business (RBP) had filed a 'Citizen's Petition' to the FDA which called for more stringent packaging standards and increased educational interventions to help lower the number of children exposed to products that contain buprenorphine - found in RBP's SUBOXONE tablets - which are used to treat opioid dependence.

"The FDA concluded that the safety data presented by RB Pharmaceuticals did not warrant these additional measures, deciding instead that existing labelling and safety programmes were sufficient," Reckitt said.

The company said that it is "disappointed" with the decision but will continue to work with the FDA on safety enhancements.

"RBP remains committed to maintaining its own high level standards for safety, including the use of child resistant, unit-dose packaging for its buprenorphine-based opioid dependence treatment products.

"It will therefore carry on with the decision to discontinue the sale of its loose tablet bottles of SUBOXONE in the United States in favour of other effective treatment options that have shown reduced paediatric exposure rates."

Reckitt makes a wide range of household cleaning products such as Cillit Bang and Calgon, but is also responsible for brands such as Nurofen and Strepsils.

Recommended

Share tips of the week – 30 September
Share tips

Share tips of the week – 30 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Sep 2022
The best British tech stocks from a thriving sector
Share tips

The best British tech stocks from a thriving sector

Move over, Silicon Valley. Over the past two decades the UK has become one of the main global hubs for tech start-ups. Matthew Partridge explains why,…
29 Sep 2022
These 3 top value stocks offer
Share tips

These 3 top value stocks offer

Professional investor Adam Rackley of Cape Wrath Capital highlights three overlooked value stocks to buy.
29 Sep 2022
Three top-notch Asian stocks to buy
Share tips

Three top-notch Asian stocks to buy

Professional investors Adrian Lim and Pruksa Iamthongthong, managers of the Asia Dragon Trust, pick three of their favourite Asian stocks to buy now.
23 Sep 2022

Most Popular

The best British tech stocks from a thriving sector
Share tips

The best British tech stocks from a thriving sector

Move over, Silicon Valley. Over the past two decades the UK has become one of the main global hubs for tech start-ups. Matthew Partridge explains why,…
29 Sep 2022
Share tips of the week – 30 September
Share tips

Share tips of the week – 30 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Sep 2022
Why everyone is over-reacting to the mini-Budget
Budget

Why everyone is over-reacting to the mini-Budget

Most analyses of the chancellor’s mini-Budget speech have failed to grasp its purpose and significance, says Max King
29 Sep 2022